SI
ALNY icon

Stephens Inc’s Alnylam Pharmaceuticals ALNY Stock Holding History

Stephens Inc’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$493K Buy
1,638
+213
+15% +$64.2K 0.01% 885
2026
Q1 		$471K Buy
1,425
+580
+69% +$197K 0.01% 872
2025
Q4 		$336K Buy
845
+146
+21% +$64.6K ﹤0.01% 994
2025
Q3 		$319K Buy
699
+64
+10% +$26.1K ﹤0.01% 1020
2025
Q2 		$207K Buy
+635
New +$176K ﹤0.01% 1160

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Stephens Inc's ALNY Position: Q2 2026 in Review

Stephens Inc increased its Alnylam Pharmaceuticals (ALNY) stake by 15% in Q2 2026, buying an estimated $64.2K and bringing the position to 1,638 shares worth $493K. The position accounts for 0.01% of the portfolio, ranked #885.

Stephens Inc first reported a position in ALNY in Q2 2025 and has held it in 5 quarters since. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Stephens Inc held 1,638 shares of Alnylam Pharmaceuticals worth $493K as of Q2 2026.
  • Stephens Inc bought 213 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $64.2K.
  • Alnylam Pharmaceuticals made up 0.01% of Stephens Inc's portfolio in Q2 2026, its #885 holding.
  • Stephens Inc first reported a position in Alnylam Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Stephens Inc's 13F filing for Q2 2026, filed 29 Jul 2026.